WO2010111264A3 - Rasagiline formulations - Google Patents

Rasagiline formulations Download PDF

Info

Publication number
WO2010111264A3
WO2010111264A3 PCT/US2010/028314 US2010028314W WO2010111264A3 WO 2010111264 A3 WO2010111264 A3 WO 2010111264A3 US 2010028314 W US2010028314 W US 2010028314W WO 2010111264 A3 WO2010111264 A3 WO 2010111264A3
Authority
WO
WIPO (PCT)
Prior art keywords
rasagiline
formulations
pharmaceutically acceptable
salt
aspects relate
Prior art date
Application number
PCT/US2010/028314
Other languages
French (fr)
Other versions
WO2010111264A2 (en
Inventor
Deepak Gupta
Nagesh Nagaraju
Sanjay Tripathi
M. Pavan Kumar
Shrikant Vitthalrao Dhoke
Suryakumar Jayanthi
Original Assignee
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Inc. filed Critical Dr. Reddy's Laboratories Ltd.
Publication of WO2010111264A2 publication Critical patent/WO2010111264A2/en
Publication of WO2010111264A3 publication Critical patent/WO2010111264A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical formulations comprising rasagiline, or a pharmaceutically acceptable salt thereof. Aspects relate to formulations prepared using rasagiline or a salt with a particle size distribution wherein about 90% of the particles have particle sizes smaller than 1000 μm, and having content uniformity such that the formulation contains 90% to 110% of the label content of rasagiline or its salt. Further aspects relate to stable pharmaceutical formulations comprising rasagiline or a pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient, wherein the formulations are substantially free of a sugar alcohol.
PCT/US2010/028314 2009-03-24 2010-03-23 Rasagiline formulations WO2010111264A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN658CH2009 2009-03-24
IN658/CHE/2009 2009-03-24
US18651809P 2009-06-12 2009-06-12
US61/186,518 2009-06-12

Publications (2)

Publication Number Publication Date
WO2010111264A2 WO2010111264A2 (en) 2010-09-30
WO2010111264A3 true WO2010111264A3 (en) 2011-02-24

Family

ID=42781817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/028314 WO2010111264A2 (en) 2009-03-24 2010-03-23 Rasagiline formulations

Country Status (1)

Country Link
WO (1) WO2010111264A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010274589A1 (en) * 2009-07-23 2012-02-16 Alkem Laboratories Ltd. Oral pharmaceutical composition of rasagiline and process for preparing thereof
EP2389927A1 (en) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
WO2012153349A2 (en) 2011-05-04 2012-11-15 Cadila Healthcare Limited Rasagiline and its pharmaceutically acceptable salts
DE102012000786A1 (en) * 2012-01-18 2013-07-18 Stada Arzneimittel Ag Process for the preparation of a solid pharmaceutical composition containing the active substance rasagiline
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
WO2014192022A1 (en) * 2013-05-20 2014-12-04 Cadila Healthcare Limited Pharmaceutical compositions of rasagiline
WO2016151466A1 (en) * 2015-03-26 2016-09-29 Unichem Laboratories Limited Process of preparing potassium salt of azilsartan medoxomil
WO2017168244A1 (en) * 2016-03-26 2017-10-05 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositons for n-propargylamine derivative
CN114469902A (en) * 2020-10-23 2022-05-13 上海上药中西制药有限公司 Sublingual film agent of rasagiline or pharmaceutical salt thereof, preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en) * 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006014973A2 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006057912A2 (en) * 2004-11-24 2006-06-01 Teva Pharmaceutical Industries, Ltd. Rasagiline orally disintegrating compositions
WO2006091657A1 (en) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity

Also Published As

Publication number Publication date
WO2010111264A2 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
WO2010111264A3 (en) Rasagiline formulations
WO2013130669A8 (en) Pharmaceutical composition and administration thereof
WO2011106416A3 (en) Abuse-resistant formulations
WO2010019239A3 (en) Pharmaceutical composition of n- [2,4-bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide and administration thereof
WO2009122301A3 (en) Rasagiline mesylate particles and process for the preparation thereof
WO2009092129A8 (en) Delayed release pharmaceutical composition of duloxetine
EP3626253A3 (en) Stable formulations of linaclotide
WO2009074286A3 (en) Pharmaceutical formulation comprising ezetimibe
MX2012001939A (en) Pharmaceutical composition and administrations thereof.
WO2011084593A3 (en) Abuse-resistant formulations
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
NZ721952A (en) Delayed release compositions of linaclotide
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
UA107499C2 (en) Dry powder formulation containing an antimuscarinic agent
WO2010021607A3 (en) Pharmaceutical formulation
WO2011067667A3 (en) Fexofenadine microcapsules and compositions containing them
WO2009050726A3 (en) Compositions and methods for improved delivery of bupropion
WO2011143118A3 (en) Alcohol-resistant formulations
WO2019059953A3 (en) Dry powder compositions with magnesium stearate
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2009039157A3 (en) Orlistat pharmaceutical formulations
WO2012087255A3 (en) Pharmaceutical formulations comprising imatinib
WO2012085284A3 (en) High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
TN2015000267A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10756713

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10756713

Country of ref document: EP

Kind code of ref document: A2